South Korea
· Delayed Price · Currency is KRW Bio Plus Statistics
Total Valuation
Bio Plus has a market cap or net worth of KRW 432.11 billion. The enterprise value is 476.03 billion.
| Market Cap | 432.11B |
| Enterprise Value | 476.03B |
Important Dates
The next estimated earnings date is Thursday, August 14, 2025.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | Dec 27, 2024 |
Share Statistics
Bio Plus has 58.87 million shares outstanding. The number of shares has increased by 5.72% in one year.
| Current Share Class | 58.87M |
| Shares Outstanding | 58.87M |
| Shares Change (YoY) | +5.72% |
| Shares Change (QoQ) | +20.72% |
| Owned by Insiders (%) | 32.71% |
| Owned by Institutions (%) | 6.35% |
| Float | 39.45M |
Valuation Ratios
The trailing PE ratio is 22.02.
| PE Ratio | 22.02 |
| Forward PE | n/a |
| PS Ratio | 5.42 |
| PB Ratio | 2.59 |
| P/TBV Ratio | 3.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 21.76 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.04, with an EV/FCF ratio of -6.45.
| EV / Earnings | 24.29 |
| EV / Sales | 5.97 |
| EV / EBITDA | 15.04 |
| EV / EBIT | 16.82 |
| EV / FCF | -6.45 |
Financial Position
The company has a current ratio of 0.80, with a Debt / Equity ratio of 0.34.
| Current Ratio | 0.80 |
| Quick Ratio | 0.49 |
| Debt / Equity | 0.34 |
| Debt / EBITDA | 1.78 |
| Debt / FCF | -0.76 |
| Interest Coverage | 99.53 |
Financial Efficiency
Return on equity (ROE) is 15.40% and return on invested capital (ROIC) is 9.51%.
| Return on Equity (ROE) | 15.40% |
| Return on Assets (ROA) | 7.71% |
| Return on Invested Capital (ROIC) | 9.51% |
| Return on Capital Employed (ROCE) | 16.53% |
| Revenue Per Employee | 659.33M |
| Profits Per Employee | 161.99M |
| Employee Count | 121 |
| Asset Turnover | 0.35 |
| Inventory Turnover | 2.84 |
Taxes
| Income Tax | -1.66B |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.82% in the last 52 weeks. The beta is 0.55, so Bio Plus's price volatility has been lower than the market average.
| Beta (5Y) | 0.55 |
| 52-Week Price Change | +24.82% |
| 50-Day Moving Average | 7,442.40 |
| 200-Day Moving Average | 6,590.23 |
| Relative Strength Index (RSI) | 40.62 |
| Average Volume (20 Days) | 479,756 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Bio Plus had revenue of KRW 79.78 billion and earned 19.60 billion in profits. Earnings per share was 333.28.
| Revenue | 79.78B |
| Gross Profit | 51.95B |
| Operating Income | 28.30B |
| Pretax Income | 21.72B |
| Net Income | 19.60B |
| EBITDA | 31.65B |
| EBIT | 28.30B |
| Earnings Per Share (EPS) | 333.28 |
Balance Sheet
The company has 29.01 billion in cash and 56.23 billion in debt, giving a net cash position of -27.22 billion or -462.42 per share.
| Cash & Cash Equivalents | 29.01B |
| Total Debt | 56.23B |
| Net Cash | -27.22B |
| Net Cash Per Share | -462.42 |
| Equity (Book Value) | 166.90B |
| Book Value Per Share | 2,567.57 |
| Working Capital | -21.75B |
Cash Flow
In the last 12 months, operating cash flow was 19.86 billion and capital expenditures -93.62 billion, giving a free cash flow of -73.76 billion.
| Operating Cash Flow | 19.86B |
| Capital Expenditures | -93.62B |
| Free Cash Flow | -73.76B |
| FCF Per Share | -1,252.93 |
Margins
Gross margin is 65.12%, with operating and profit margins of 35.48% and 24.57%.
| Gross Margin | 65.12% |
| Operating Margin | 35.48% |
| Pretax Margin | 27.23% |
| Profit Margin | 24.57% |
| EBITDA Margin | 39.67% |
| EBIT Margin | 35.48% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 50.00, which amounts to a dividend yield of 0.69%.
| Dividend Per Share | 50.00 |
| Dividend Yield | 0.69% |
| Dividend Growth (YoY) | -28.57% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 21.41% |
| Buyback Yield | -5.72% |
| Shareholder Yield | -4.99% |
| Earnings Yield | 4.54% |
| FCF Yield | -17.07% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on November 23, 2022. It was a forward split with a ratio of 4.
| Last Split Date | Nov 23, 2022 |
| Split Type | Forward |
| Split Ratio | 4 |
Scores
Bio Plus has an Altman Z-Score of 2.82 and a Piotroski F-Score of 6. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.82 |
| Piotroski F-Score | 6 |